EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rational treatment options for T1/2N0M0 squamous cell carcinoma of the anal canal: a population-based study combined with external validation

Xue Shao, Qiulei Zhang, Ying Huo, Chang Lu iD

The Oncologist · 2024

DOI: 10.1093/oncolo/oyae068 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2024. Verfasst von Xue Shao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatopancreatobiliary Medicine, The Second Hospital of Jilin University, Changchun, People's Republic of China. Hauptthemen laut MEDLINE: Carcinoma, Squamous Cell, Anus Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wu Jieping Medical Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Treatment options for T1/2N0M0 anal squamous cell carcinoma include chemotherapy, radiotherapy, chemoradiotherapy, and local excision, although the optimal treatment method has not been determined.

Methods

The National Cancer Institute Surveillance, Epidemiology and Results database was used to search and screen 1465 patients with cT1/2N0M0 anal squamous cell carcinoma who were clinically diagnosed between 2004 and 2016. Survival analysis was performed using the Kaplan-Meier method and log-rank test. Cox proportional hazards regression analysis was performed to screen independent prognostic factors and build a nomogram survival prediction model. According to the risk score, patients were divided into low, medium, and high risk groups using X-tile software.

Results

Age, sex, grade and cT stage were identified as independent prognostic factors for cT1/2N0M0 anal squamous cell carcinoma and were included in the nomogram to construct a prediction model. The C-index of the model was 0.770 [95% confidence interval (CI), 0.693-0.856], which was higher than the C-index of T stage 0.565 (95% CI, 0.550-0.612). Low-risk patients benefited from local resection, moderate-risk patients benefited from radiotherapy, and high-risk patients benefited from radiotherapy or chemoradiotherapy. This was confirmed using external validation data from the center.

Conclusion

The nomogram developed in this study effectively and comprehensively evaluated the prognosis of patients with cT1/2N0M0 squamous cell carcinoma of the anal canal. Local excision is recommended for low risk patients, radiotherapy for moderate-risk patients, and radiotherapy or chemoradiotherapy for high-risk patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Squamous CellAnus NeoplasmsHumansMaleFemaleMiddle AgedAgedNomogramsPrognosisNeoplasm StagingAdultSEER ProgramAged, 80 and over

Stichwörter der Autor:innen

cT1/2N0M0 squamous cell carcinoma of the anal canalnomogramprognosisrational treatment

Autor:innen und Institutionen

  • Department of Hepatopancreatobiliary Medicine, The Second Hospital of Jilin University, Changchun, People's Republic of China.
  • Department of Anesthesiology, The Second Hospital of Jilin University, Changchun, People's Republic of China.

ORCID-Profile: Chang Lu

Förderung

  • Wu Jieping Medical Foundation

Zitieren

APA

Shao, X., Zhang, Q., Huo, Y., & Lu, C. (2024). Rational treatment options for T1/2N0M0 squamous cell carcinoma of the anal canal: a population-based study combined with external validation. The Oncologist. https://doi.org/10.1093/oncolo/oyae068

Vancouver

Shao X, Zhang Q, Huo Y, Lu C. Rational treatment options for T1/2N0M0 squamous cell carcinoma of the anal canal: a population-based study combined with external validation. The Oncologist. 2024. doi:10.1093/oncolo/oyae068

BibTeX
@article{Shao2024,
  author = {Shao, Xue and Zhang, Qiulei and Huo, Ying and Lu, Chang},
  title = {Rational treatment options for T1/2N0M0 squamous cell carcinoma of the anal canal: a population-based study combined with external validation},
  journal = {The Oncologist},
  year = {2024},
  doi = {10.1093/oncolo/oyae068}
}
Kostenlos starten →